(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) on Tuesday said the FDA has accepted the company's supplemental New Drug Application for Purified Cortrophin Gel for multiple indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.
A decision by the FDA on the application is expected on October 29, 2021.
"We look forward to further productive engagement with the FDA, and in parallel, we are focused on preparations for the launch of Cortrophin Gel," stated Nikhil Lalwani, Chief Executive Officer of ANI Pharmaceuticals.
Purified Cortrophin Gel is a purified adrenocorticotropic hormone (ACTH) previously approved in the U.S. for indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
